ML-007C-MA

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Psychosis Associated With Alzheimer's Disease

Conditions

Psychosis Associated With Alzheimer's Disease

Trial Timeline

Mar 1, 2026 → Mar 1, 2029

NCT ID

NCT07459660

About ML-007C-MA

ML-007C-MA is a phase 2 stage product being developed by MapLight Therapeutics for Psychosis Associated With Alzheimer's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07459660. Target conditions include Psychosis Associated With Alzheimer's Disease.

What happened to similar drugs?

3 of 17 similar drugs in Psychosis Associated With Alzheimer's Disease were approved

Approved (3) Terminated (1) Active (14)

🔄Paliperidone ERJohnson & JohnsonPhase 3

🔄Quetiapine FumarateAstraZenecaPhase 3

🔄Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3

✅ZiprasidonePfizerApproved

✅ziprasidone + Standard therapyPfizerApproved

🔄Xanomeline/trospiumBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07459660	Phase 2	Recruiting	Mar 1, 2026	Mar 1, 2029	Psychosis Associated With Alzheimer's Disease
NCT07459647	Phase 2	Recruiting	Mar 1, 2026	Feb 1, 2030	Schizophrenia

Competing Products

20 competing products in Psychosis Associated With Alzheimer's Disease

See all competitors

Product	Company	Stage	Hype Score
Paliperidone ER	Johnson & Johnson	Phase 3	40
Saracatinib + Placebo Oral Tablet	AstraZeneca	Phase 1	25
Quetiapine Fumarate	AstraZeneca	Phase 3	40
Quetiapine fumarate (Seroquel) SR	AstraZeneca	Phase 3	40
Quetiapine fumarate (Seroquel) SR	AstraZeneca	Phase 3	40
SCH 900460	Merck	Pre-clinical	26
Ziprasidone	Pfizer	Approved	43
ziprasidone + Standard therapy	Pfizer	Approved	35
ziprasidone	Pfizer	Pre-clinical	26
Xanomeline/trospium	Bristol Myers Squibb	Phase 3	47
Memantine + Placebo	Lundbeck	Phase 1	33
Haloperidol 10 mg Tablets (Cord Laboratories) + Haldol 10 mg Tablets (McNeil Pharmaceuticals)	Sandoz Group	Phase 1	26
Cannabidiol (CBD) + Placebo	Jazz Pharmaceuticals	Phase 3	44
Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + Placebo	Acadia Pharmaceuticals	Phase 3	37
Pimavanserin	Acadia Pharmaceuticals	Approved	40
pimavanserin tartrate + placebo	Acadia Pharmaceuticals	Phase 3	37
Placebo + Pimavanserin 34 mg + Pimavanserin 20 mg	Acadia Pharmaceuticals	Phase 3	37
ACP-204 + Placebo	Acadia Pharmaceuticals	Phase 2/3	42
pimavanserin tartrate (ACP-103)	Acadia Pharmaceuticals	Phase 2	32
Pimavanserin tartrate + Placebo	Acadia Pharmaceuticals	Phase 2	32